The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer

Table 4 Selected published trials on EBRT with HDR-BT in prostate cancer

Study	scheme	dose	EQD ₂ α/β = 1.5 Gy	EQD ₂ α/β = 3 Gy	5-year bRFS		5-year OS
Hoskin 2007/2012 [10,11] (7-year survival)	EBRT -BT	35.75Gy/13fx + 2x8.5Gy	92 Gy	80.21 Gy	75% (66%)		88% (81%)
Hoskin 2007/2012 [10,11] (7-year survival)	EBRT	55Gy/20fx	66.8 Gy	63.25 Gy	61% (48%)		89% (81%)
Guix 2010/2011 [12,13]	EBRT -BT	46 Gy/23fx + 2x8Gy	89.4 Gy	81.2 Gy	IR	HR	-
	EBRT -BT	46 Gy/23fx + 2x8Gy	89.4 Gy	81.2 Gy	97%	96%	-
	EBRT	76 Gy/38fx	76 Gy	76 Gy	90%	89%	-
Zwahlen 2010 [14] (7-year survival)	EBRT -BT	46 Gy/23fx + 3x6Gy or 4x5Gy	82.1-84.6 Gy	78-78.4 Gy	82.5% (80.3%)		91.9% (89.5%)
Zwahlen 2010 [14] (7-year survival)	EBRT	70 Gy/35fx	70 Gy	70 Gy	81.3% (71%)		88.7% (86.2%)
Kestin 2000 [16]	EBRT + HDR-BT	46 Gy/23fx + 2-3x5.5-10.5Gy	79-118 Gy	74.1-102.7 Gy	67%		-
Kestin 2000 [16]	EBRT	66 Gy/33fx	66 Gy	66 Gy	44%		-
This study (7-year survival)	EBRT + HDR-BT	54Gy/27fx + 1x10Gy	86.8 Gy	80 Gy	67% (59%)		85% (80%)
This study (7-year survival)	EBRT	74Gy/37fx	74 Gy	74 Gy	81% (76%)		85% (73%)

ISSN: 1748-717X